Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Cash and Equivalents of $51.09 million for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $51.09M | +124.1% |
| 2024 | $22.79M | -82.8% |
| 2023 | $132.32M | +761.2% |
| 2022 | $15.37M | -88.3% |
| 2021 | $131.65M | +126.4% |
| 2020 | $58.15M | -10.6% |
| 2019 | $65.07M | +11.5% |
| 2018 | $58.34M | +13.5% |
| 2017 | $51.40M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $55.98M | +66.3% | +322.9% |
| June 30, 2025 | $13.24M | -95.8% | +30.9% |
| March 31, 2025 | $10.12M | -96.9% | -55.6% |
| December 31, 2024 | $22.79M | -82.8% | -32.3% |
| September 30, 2024 | $33.67M | -78.6% | -89.3% |
| June 30, 2024 | $314.17M | +680.0% | -4.7% |
| March 31, 2024 | $329.72M | +1320.5% | +149.2% |
| December 31, 2023 | $132.32M | +761.2% | -15.9% |
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +124.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Dianthus Therapeutics, Inc. /DE/’s cash and equivalents has declined by 0.6% (from $51.40 million to $51.09 million).
- The most recent figure is from Dianthus Therapeutics, Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: